John Libbey Eurotext

European Journal of Dermatology


Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study Volume 27, numéro 4, July-August 2017

  • [1] Surjana D., Halliday G.M., Damian D.L. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids. 2010;2010.
  • [2] Surjana D., Halliday G.M., Martin A.J. Oral Nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol. 2012;132:1497-1500.
  • [3] Chen A.C., Damian D.L. Nicotinamide and the skin. Australas J Dermatol. 2014;55:169-175.
  • [4] Chen A.C., Martin A.J., Choy B. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373:1618-1626.
  • [5] Rosen T., Lebwohl M.G. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68:S2-9.
  • [6] Diepgen T.L., Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146:1-6.
  • [7] Halliday G.M. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res. 2005;571:107-120.
  • [8] Lindelöf B., Sigurgeirsson B., Gabel H., Stern R.S. Incidence of skin cancer in 5,356 patients following organ transplantation. Br J Dermatol. 2000;143:513-519.
  • [9] Kempf W., Mertz K.D., Hofbauer G.F. Skin cancer in organ transplant recipients. Pathobiology. 2013;80:302-309.
  • [10] Poon T.S., Barnetson R.S., Halliday G.M. Prevention of immunosuppression by sunscreens in humans is unrelated to protection from erythema and dependent on protection from ultraviolet A in the face of constant ultraviolet B protection. J Invest Dermatol. 2003;121:184-190.
  • [11] Niren N. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis. 2006;11:11-16.
  • [12] Gensler H.L., Williams T., Huang A.C., Jacobsen E.L. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer. 1999;34:36-41.
  • [13] Yiasemides E., Sivapirabu G., Halliday G.M., Park J., Damian D.L. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis. 2009;30:101-105.
  • [14] Moloney F.J., Vestergaard M.E., Radojkovic B.L., Damian D.L. Randomised, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol. 2010;162:1138-1139.
  • [15] Park J., Halliday G.M., Surjana D. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol. 2010;86:942-948.
  • [16] Gero D., Szabo C. Poly (APD-ribose) polymerase: a new therapeutic target? Curr Opin Anaesthesiol. 2008;21:111-121.
  • [17] Jacobson E.L., Giacomoni P.U., Roberts M.J., Wondrak G.T., Jacobson M.K. Optimizing the energy status of skin cells during solar radiation. J Photochem Photobiol B. 2001;63:141-147.
  • [18] Boyonoski A.C., Gallacher L.M., ApSimon M.M. Niacin deficiency increases the sensitivity of rats to the short and long term effects of ethylnitrosourea treatment. Mol Cell Biol. 1999;193:83-87.
  • [19] Kirkland J.B. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther. 2009;8:725-732.
  • [20] Drago F., Ciccarese G., Parodi A. Nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2016;374:789-790.
  • [21] Chen A.C., Martin A.J., Dalziell R.A. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016;75:1073-1075.